Publication | Open Access

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

VaccinationVaccine SafetyVaccine DevelopmentImmunologyProtein-adjuvant VaccinesVirologyVaccine EfficacyNon-inferiority TrialPhase 2MedicineCovid-19